Harbin Medisan Pharmaceutical Co., Ltd.

Equities

002900

CNE1000032V9

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
9.87 CNY -1.60% Intraday chart for Harbin Medisan Pharmaceutical Co., Ltd. -10.76% -27.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023 CI
Medisan Pharma's Potassium Chloride Injection Passes Drug Regulator's Evaluation MT
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves the Cash Dividend for the Year 2022, Payable on May 31, 2023 CI
Harbin Medisan Pharma Gets Patent Rights of China Pharmaceutical University-Developed Drug MT
Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022 CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Management Appointments CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Harbin Medisan Pharmaceutical Co., Ltd. Implements Final Cash Dividend for 2021, Payable on June 13, 2022 CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Final Cash Dividend Proposal for 2021 CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Cash Dividend Proposal for 2021 CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2020, Payable on July 5, 2021 CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2020 CI
Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2020 CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021 CI
Harbin Fuerjia Technology Development Co., Ltd. completed the acquisition of Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd.. CI
Harbin Fuerjia Technology Development Co., Ltd. agreed to acquire Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd. for CNY 570 million. CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Chart Harbin Medisan Pharmaceutical Co., Ltd.
More charts
HARBIN MEDISAN PHARMACEUTICAL CO LTD is a China-based company principally engaged in the research and development, production and sales of chemical preparations, active pharmaceutical ingredients (APIs), medical devices and cosmetics. Its medicines cover the nervous system, cardio-cerebrovascular, systemic anti-infection, musculoskeletal, nutritional infusion, and body fluid balance infusion therapeutic fields. The Company's products include freeze-dried powder injections, small volume injections, large infusion products, solid preparations, medical devices and cosmetics. The Company mainly distributes its products within domestic market.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 002900 Stock
  4. News Harbin Medisan Pharmaceutical Co., Ltd.
  5. Harbin Medisan Pharma Gets Patent Rights of China Pharmaceutical University-Developed Drug